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Abstract
Summary The objectives of this study were to estimate per-
sistence with denosumab and put these results in context by
conducting a review of persistence with oral bisphosphonates.
Persistence with denosumab was found to be higher than with
oral bisphosphonates.
Purpose This study had two objectives: to analyse persistence
in Swedish women initiating denosumab for treatment of post-
menopausal osteoporosis (PMO) and to put these findings in
context by conducting a literature review and meta-analysis of
persistence data for oral bisphosphonates.
Methods The study used the Swedish PrescribedDrug Register
and included women aged at least 50 years initiating
denosumab between May 2010 and July 2012. One injection
of denosumab was defined as 6-month persistence. Women
were considered persistent for another 6 months if they filled
their next prescription within 6 months+56 days and survival
analysis applied to the data. A literature search was conducted
in PubMed to identify retrospective studies of persistence with
oral bisphosphonates and pooled persistence estimates were
calculated using a random-effects model.
Results The study identified 2,315 women who were incident
denosumab users. Mean age was 74 years and 61 % had been
previously treated for PMO. At 12 and 24 months, persistence
with denosumab was 83 % (95 % CI, 81–84 %) and 62 %
(95 % CI, 60–65 %), respectively. The literature search iden-
tified 40 articles for inclusion in the meta-analysis. At 12 and
24months, persistence with oral bisphosphonates ranged from
10% to 78% and from 16% to 46%, with pooled estimates of
45 % and 30 %, respectively.
Conclusion These data from the Swedish Prescribed Drug
Register and literature review suggest that persistence was
higher with denosumab than with oral bisphosphonates.
Keywords Bisphosphonates . Denosumab .Meta-analysis .
Persistence . Retrospective . Review
Introduction
Osteoporosis is a disease characterized by excessive bone resorp-
tion leading to reduced bone strength and an increased risk of
fracture. In women, reduced oestrogen levels during or after
menopause can lead to postmenopausal osteoporosis (PMO) [1].
There are several treatments available for osteoporosis, which
have the primary aim of reducing the risk of fracture [2, 3]. For
optimal outcomes, patients need to take their treatment according
to the dosing instructions and for the prescribed duration (i.e.,
they need to be both compliant and persistent with therapy) [4].
Studies in both theUSA and Europe have shown that persistence
with osteoporosis treatment is important for reducing the risk of
fracture [5–7]. The data indicate that, compared with treatment
lasting for less than 1-month, treatment must extend beyond
1 year in order to significantly reduce 3-year fracture incidence
[6]. Evidence suggests, however, that approximately 50 % of
women do not follow their prescribed osteoporosis treatment
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regimen and 50 % discontinue treatment within 1 year [8, 9].
Hence, persistence is an important consideration in the overall
management of patients with osteoporosis. Moreover, modelling
studies have shown that the incorporation of persistence in health
economic evaluations can have a considerable impact on the
estimated cost-effectiveness of an intervention [10, 11].
Oral bisphosphonates (BPs), including both alendronate and
risedronate, are the current mainstay of anti-osteoporosis treat-
ment in Europe [12]. Oral BPs can be administered daily, week-
ly, or monthly. An alternative treatment option is denosumab, a
fully human monoclonal antibody that inhibits the RANK li-
gand, which is administered as a 60-mg subcutaneous injection
once every 6 months. Denosumab 60 mg is indicated for the
treatment of osteoporosis in postmenopausal women and in
men at increased risk of fracture, and for the treatment of bone
loss associated with hormone ablation in men with prostate
cancer at increased risk of fracture [13]. Denosumab 60 mg
has also been shown to increase bonemass in womenwith bone
loss associated with adjuvant aromatase inhibitor therapy [14].
In patients with osteoporosis, the long-interval subcutaneous
dosing regimen of denosumab could enable higher persistence
with therapy than that observed with other anti-osteoporosis
treatments [7, 9]. Indeed, levels of 12-month persistence have
been reported with denosumab that vastly exceed the 50 % rate
cited above. In a randomized, cross-over trial comparing
denosumab with alendronate, 91 % of patients were persistent
with treatment over 12 months, whilst in two single-arm, pro-
spective, observational studies conducted in the USA, Canada,
Austria, Belgium, Greece, and Germany, 12-month persistence
rates varied from 82 to 94 % across countries [15–17]. To our
knowledge, however, no study of real-world persistence with
denosumab therapy in Sweden has yet been published.
This study had two objectives. The first was to estimate
persistence in Swedish women in whom denosumab treatment
was initiated for PMO and to explore patient characteristics
that might affect persistence. The second was to put the find-
ings regarding persistence with denosumab into context by
conducting a literature review and meta-analysis of published,
retrospective data on persistence with oral BPs.
Methods
Persistence with denosumab
Data source and patient selection
This study involved the analysis of data from the Swedish
Prescribed Drug Register, which contains information on
drugs dispensed on prescription since 2005 for the Swedish
population (approximately 9.6 million individuals) [18]. Mor-
tality data were collected from the Swedish Causes of Death
Register, which includes death dates for all people residing in
Sweden at the time of death. Swedish national registers have a
high degree of accuracy. The loss of patient information from
the Swedish Prescribed Drug Register is less than 0.6 % of all
possible values and fewer than 0.5 % of all deaths are missing
from the Causes of Death Register [19].
Women aged 50 years or older in whom denosumab treat-
ment was initiated between 1 May 2010 and 31 July 2012
were identified in the Swedish Prescribed Drug Register. To
capture relevant baseline characteristics, data needed to be
available for at least the 18-month period before treatment
initiation (the pre-index period). Similarly, to accumulate suf-
ficient follow-up time to study persistence, data needed to be
available for at least the 8-month period immediately follow-
ing treatment initiation. The analysis focused on women with
PMO and included only those receiving denosumab 60 mg.
As denosumab is also used to increase bone mass in patients
with bone loss associated with adjuvant aromatase inhibitor
therapy, patients filling prescriptions for aromatase inhibitors
in the pre-index period were excluded from the study.
Definition of persistence
Persistence was defined as the number of days from the date of
treatment initiation to the end of the duration of the last filled
prescription or the end of the study period (31 March 2013).
One injection of denosumab equated to 6 months’ persistence;
hence, all women were defined as being persistent with ther-
apy for at least 6 months. Women were considered to be per-
sistent for an additional 6 months if they filled their next
denosumab prescription within 6 months+56 days of admin-
istration of the previous injection (i.e., a gap of 56 days was
permitted) [4].Women failing to refill their prescription before
the end of the permissible gap were defined as being non-
persistent 6 months after the last filled prescription.
Covariates
The covariates used in the analysis were: age; previous oste-
oporosis treatment in the pre-index period; glucocorticoid use,
defined as filling a prescription for cortisone, hydrocortisone,
methylprednisolone, prednisolone, prednisone, triamcinolone,
betamethasone, or dexamethasone equivalent to at least
450 mg of prednisolone in the pre-index period [20]; concur-
rent calcium and/or vitamin D supplementation, defined as
filling prescriptions corresponding to at least 109,500 mg of
calcium (1,200 mg/day for 3 months) and/or 73,000 IU of
vitamin D (800 IU/day for 3 months) in the 6 months after
treatment was initiated [21]; dependency, defined as living in a
dependent/institutionalized setting (determined on the basis of
the initial prescription being pre-dispensed); and receiving
primary care (defined as the initial prescription being pre-
scribed in the primary care setting).
2402 Osteoporos Int (2015) 26:2401–2411
Statistical analyses
Persistence with therapy was estimated at 12, 18, and
24 months using Kaplan–Meier survival curves, with non-
persistence as the failure event. Women were censored for
death and end of data availability (31March 2013). Covariates
associated with non-persistence were investigated using a
parametric proportional hazards model (Weibull distribution).
The effects of alternative permissible gaps of 30, 90, and
180 days were explored using sensitivity analyses.
Denosumab has a biannual dosing regimen and women may
refill their prescriptions several months earlier than the date on
which the next injection is needed, which can result in long
gaps between prescriptions. This possible accumulation of
denosumab was accounted for in another sensitivity analysis,
which used a 56-day permissible gap and permitted women to
cover future gaps between filled prescriptions with previously
dispensed medication.
Subgroup analyses were conducted according to the calen-
dar year of the index denosumab injection. Further subgroup
analyses compared persistence in treatment-naïve women
with that in treatment-experienced women. The latter group
was defined as those with a prescription for another anti-
osteoporosis drug (alendronate, risedronate, ibandronate, eti-
dronate, zoledronic acid, strontium ranelate, raloxifene, or
parathyroid hormone analogue) in the pre-index period.
Model distribution and covariate selection were based on
maximizing the log-likelihood and minimizing the Akaike
information criterion. The proportional hazards assumption
was tested by graphical inspection and by exploring whether
the included covariates significantly varied over time. The
statistical analysis was executed using Stata 12 (StataCorp
LP, College Station, TX, USA).
Persistence with oral bisphosphonates
Literature review
The literature review focused on persistence with oral BPs,
which are the most commonly used treatments for osteopo-
rosis in Europe and the USA [1]. Retrospective studies that
estimated treatment persistence with oral BPs at 12 and
24 months were identified in the PubMed database. The
search string used was Bosteoporo*[All fields] AND
(persistence[All fields] OR adherence[All fields] OR
compliance[All fields] OR discontin*[All fields]) AND
(register*[All fields] OR claim*[All fields] OR record*[All
fields] OR health plan*[All fields] OR pharmacy*[All
fields] OR prescript*[All fields]) OR (osteoporosis[All
fields] AND persistence[All fields])^. Searches also includ-
ed the MeSH terms Bpatient compliance^, Bcompliance^,
Bpostmenopausal^, and Bosteoporosis^. The search
encompassed all articles published until 22 November
2013 with an English-language abstract.
In addition to the PubMed database search, seven review
articles [22–28] were cited in the papers included after the
literature search and full-text review. These review articles
were manually searched to identify articles not found using
the search string. To be included in this study, an article need-
ed to present at least one estimate of 12- and 24-month per-
sistence with oral BP treatment. No additional inclusion
criteria were used.
Statistical analyses
Pooled estimates of persistence at 12 and 24 months were
calculated using a random-effects model [29]. Subgroup anal-
yses of 12-month persistence were conducted according to
frequency of administration (weekly and daily; only for those
studies directly comparing these two frequencies) and region




The final cohort consisted of 2,315 incident users of
denosumab (Fig. 1) who contributed a total of 2,747 person-
years. Baseline patient characteristics are presented in Table 1.
Women were followed up for a mean (median) of 433 (387)
days, until censoring or non-persistence with therapy. The
majority (61 %) of women had received another anti-
osteoporosis treatment in the 18 months before starting
denosumab treatment. Approximately two fifths of women
were prescribed their initial prescription medication in a pri-
mary care setting, and approximately one fifth had received
glucocorticoids before initiation of denosumab treatment.
Even though the inclusion period continued to 31 July 2012,
the majority (62 %) of women filled their index prescription in
2010 or 2011.
Persistence
The estimated Kaplan–Meier curves for persistence with
denosumab are presented in Fig. 2. Using a permissible gap
of 56 days, persistence with denosumab treatment was 83 %
(95 % CI, 81–84 %) at 12 months, 69 % (95 % CI, 67–71 %)
at 18 months, and 62 % (95 % CI, 60–65 %) at 24 months.
Increasing the permissible gap to 90 and 180 days, 12-month
persistence was 84% (95%CI, 83–86%) and 87% (95%CI,
86–88 %), respectively. Decreasing the permissible gap to
30 days, 12-month persistence was 78 % (95 % CI, 76–79 %).
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The sensitivity analysis allowing patients to have overlap-
ping prescriptions showed results similar to the analysis with a
permissible gap of 90 days (data not shown).
At 24 months, women who had received previous anti-
osteoporosis treatment (during the pre-index period) were
more likely to be persistent with therapy than those who had
not (65 vs. 58 %, p<0.001); no difference was observed at
12 months (p=1.000). No difference in 12-month persistence
was found between women whose denosumab treatment was
initiated in 2010 or 2011 and those first receiving denosumab
in 2012 (p=1.000).
Determinants of non-persistence
A multivariate Weibull model was fitted to identify variables
that were significantly associated with non-persistence
(Table 2). For all included covariates, no significant evidence
of non-proportional hazards was observed (data not shown).
Previous anti-osteoporosis treatment (during the pre-index
period) was associated with a higher rate of persistence
compared with no previous treatment. Filling a prescription
for calcium and vitaminD supplementation in the first 6months
after denosumab initiation was also found to be associated with
a higher persistence rate. Glucocorticoid treatment during the
pre-index period was associated with a lower denosumab






Previous anti-osteoporosis treatmentc 1,406 (60.7)
Glucocorticoid used 483 (20.9)
Concurrent calcium/vitamin D supplementatione 826 (35.7)
Dependency/institutionalizedf 98 (4.2)
Primary careg 903 (39.0)
Filling first prescription in 2010 or 2011 1,426 (61.6)
Filling first prescription in 2012 889 (38.4)
Data are mean±standard deviation or n (%)
a Time until censoring or non-persistence
bAge of patient at initiation of denosumab treatment
c Experience of any other anti-osteoporosis treatment in the 18 months
before initiation of denosumab treatment
d Filling prescriptions equivalent to at least 450 mg of prednisolone in the
18 months before initiation of denosumab treatment
e Filling prescription for calcium and vitamin D supplements in the
6 months after initiation of denosumab treatment
f Receiving initial denosumab prescription as pre-dispensed
g Initial denosumab prescription prescribed in the primary care setting
Fig. 1 Flow chart of the selection
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Fig. 2 Kaplan–Meier estimates of persistence with denosumab therapy
for permissible gaps of different lengths
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persistence rate. Age, pre-dispensing of the initial prescription,
and receiving treatment in the primary care setting did not have
significant effects on persistence levels.
Literature review andmeta-analysis: persistence with oral
bisphosphonates
Included articles
The search of the PubMed database identified 663 articles,
most of which were excluded on the basis of their title or
abstract (Fig. 3). The most frequent reasons for exclusion
were: not reporting an estimate of 12- or 24-month persis-
tence; discussing only hormone replacement therapy, osteopo-
rotic fractures, or calcium/vitamin D supplementation; not
using retrospective data; not having been written in English;
and being a review. Review articles were manually searched
for any articles that had not been identified by the search of
PubMed [22, 28].
In total, 40 articles were included in the final review and
meta-analysis (Table 3) [5, 6, 30–67]. These included studies
from 12 different countries, with the largest number of studies
being conducted in the USA (17 studies) [5, 35–38, 41, 42, 46,
49–51, 54, 56, 59, 63, 64, 66] and the next largest number
being conducted in the Netherlands (four studies) [43, 44, 48,
61]. Two studies used the Swedish Prescribed Drug Register
[6, 47]. In the majority of studies, a patient was defined as
non-persistent with treatment if the time period between two
consecutive prescription fills exceeded the length of the per-
missible gap. The most commonly used permissible gap was
30 days [5, 30, 32–40, 44, 49, 52, 55, 56, 58, 61, 65]; other
commonly used permissible gaps were 60 and 90 days. In nine
studies [6, 31, 40–42, 45, 47, 64, 66], patients were allowed to
accumulate medicine (i.e., use supply from a previous pre-
scription) and in 16 studies [6, 30–32, 34, 39, 40, 44–46, 52,
54, 55, 57, 61, 63], they were allowed to switch between
treatments during the study period (e.g., from alendronate to
risedronate or from weekly to daily oral BPs). The studies
varied in the type of data source used (e.g., claims, medical
charts), type of patients included (e.g., women with PMO,
treatment-naïve women), and type of oral BP prescribed
(e.g., alendronate, risedronate).
Persistence at 12 and 24 months
Of the 40 included studies, 39 reported at least one estimate of
12-month persistence with treatment (Fig. 4) [6, 30–67] and
17 [5, 6, 31, 32, 37, 45, 46, 48, 50–52, 55, 58, 59, 61, 64, 65]
reported at least one estimate of 24-month persistence
(Table 3). Estimates of 12-month persistence varied widely,
from 10 to 78 %, with the majority of estimates ranging from
30 to 60 %, and there was a large amount of heterogeneity
between studies in the methods used (Fig. 4). The pooled
estimate of 12-month persistence with oral BP therapy was
45 % (95 % CI, 41–49 %). Estimates of 24-month persistence
ranged from 16 to 46% (Table 3), and the pooled estimate was
30 % (95 % CI, 25–35 %). In Sweden, 12-month persistence
with oral BPs was reported to be 51 % [6], and 52 % (in
patients starting treatment in 2009) or 67 % (in those starting
treatment in 2006) [47], and 24-month persistence reported to
be 25 % [6] (Table 3).
Studies investigating the differences between daily and
weekly oral BPs [30, 35–37, 50, 55] reported that daily ad-
ministration was associated with lower 12-month persistence
compared with weekly administration (pooled estimates: 36
vs. 48 %, respectively) (Fig. 4). North American studies had a
slightly lower pooled estimate of 12-month persistence com-
pared with European studies (43 % based on 19 studies vs.
46 % based on 16 studies) (Fig. 4). The pooled 12-month
estimate of persistence in other regions (based on four studies)
was higher than the European and North American estimates.
The results of studies varying the permissible gap all indicated
that wider permissible gaps were associated with higher per-
sistence with treatment [6, 31, 33, 41, 45, 49, 51, 63, 64, 66].
Discussion
For optimal clinical outcomes, women with PMO need to
persist with anti-osteoporosis medications for the prescribed
treatment duration. To the best of our knowledge, this is the









Age 1.00 0.99–1.01 0.48
Previous anti-osteoporosis treatmenta 0.85 0.73–0.98 0.03




Dependency/institutionalizedd 0.97 0.66–1.43 0.88
Primary caree 1.09 0.94–1.27 0.25
A hazard ratio >1 indicates a higher probability of discontinuing treat-
ment relative to continuing treatment. Estimated model parameters: con-
stant=0.20 and p=1.49
a Experience of any other anti-osteoporosis treatment in the 18 months
before initiation of denosumab treatment
b Filling prescriptions equivalent to at least 450 mg of prednisolone in the
18 months before initiation of denosumab treatment
c Filling prescriptions for calcium and/or vitamin D supplements in the
6 months after initiation of denosumab treatment
d Receiving initial denosumab prescription as pre-dispensed
e Initial denosumab prescription prescribed in the primary care setting
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Identified articles (
Remaining articles (n=158) 
Remaining articles (n=79) 
Excluded by title review (n=505) 
Excluded by abstract review (n=79) 
Excluded by full-text review (n=40) 




Fig. 3 Flow chart of the literature
search
Table 3 Summary of data included in the literature review











USA 92,839 ALE–IBA–RIS–other 100 60 days 42/30
Brankin et al. (2006) [30] UK 15,330 ALE–RIS 100 30 days Weekly vs. daily
GPRD: 52/– vs. 40/–
MEDIPLUS: 44/– vs. 33/–
DIN-LINK: 70/– vs. 56/–
Burden et al. (2012) [31] Canada 451,113 ALE–ETI–RIS 84 60 days 63/46
Cheen et al. (2012) [32] Singapore 798 ALE–RIS 92 30 days 69/18
Cheng et al. (2013) [58] Taiwan 2,975 ALE–other 90 30 days 51/38
Chiu et al. (2013) [65] Taiwan 333 ALE–other 0 30 days 46/30
Cotte et al. (2008) [34] France 2,468 ALE–ETI–RIS–other 100 30 days Previous fracture: 34/–
No previous fracture: 41/–




Cramer et al. (2005) [35] USA 2,741 ALE–RIS 100 30 days Weekly: 44/–
Daily: 32/–
Cramer et al. (2006) [36] USA 15,640 ALE–RIS 100 30 days Weekly vs. daily
USA: 44/– vs. 32/–
UK: 52/– vs. 40/–
France: 51/– vs. 44/–
Curtis et al. (2006) [59] USA 1,158 ALE/RIS 77–80 90 days ALE: 52/40
RIS: 50/40
Gallagher et al. (2008) [53] UK 44,531 ALE–RIS 81 90 days 58/–
Gold et al. (2007) [37] USA 4,769 ALE 100 30 days Weekly: 36/24
Daily: 26/16
Gold et al. (2009) [54] USA 263,383 IBA/RIS 93–94 90 days IBA: 18/–
RIS: 40/–
Hadji et al. (2012) [55] Germany 4,147 ALE–ETI–IBA–RIS–other 100 30 days 28/13
Hansen et al. (2013) [57] Denmark 100,556 Not specified 85 56 days 61/–
Huybrechts et al. (2006) [38] USA 38,120 ALE–RIS–other 100 30 days 78/–
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first retrospective register study of persistence among Swedish
women in whom denosumab therapy was initiated for the
treatment of PMO. Twelve-month persistence with
denosumab treatment was 83 %. This result is similar to pre-
viously reported estimates of persistence with denosumab
[15–17] and is higher than previously published estimates of
persistence with oral BPs. Indeed, this study’s pooled estimate
from 39 studies of oral BPs showed that only 45 % of patients
were persistent with treatment after 12 months.
Persistence with denosumab
The women included in our database study were slightly older
than those included in a study of treatment-naïve users of oral
Table 3 (continued)









Jones et al. (2008) [39] Canada 62,897 ALE/RIS 100 30 days ALE: 56/–
RIS: 54/–
Landfeldt et al. (2012) [6] Sweden 56,586 ALE–RIS–other 86 56 days 51/25
Li et al. (2012) [40] UK 66,116 ALE–ETI–IBA–RIS–other 100 30 days 32/–
Lo et al. (2006) [41] USA 13,455 ALE 100 60 days 50/–
McCombs et al. (2004) [42] USA 3,720 ALE–ETI–RIS 93 14 days 24/–
McGowan et al. (2013) [60] Ireland 1,565 Not specified Not reported 35 days Urban: 46/–
Rural: 50/–
Netelenbos et al. (2011) [43] Netherlands 8,626 ALE–RIS–other 80 183 days 43/–
Penning-van Beest et al.
(2006) [44]
Netherlands 2,124 ALE–ETI–RIS 100 30 days 43/–
Rabenda et al. (2008) [45] Belgium 54,807 ALE 100 35 days 40/25






Siris et al. (2006) [5] USA 35,537 ALE–RIS 100 30 days –/20
Solomon et al. (2005) [46] USA 40,002 ALE–RIS–other 96 120 days 55/40
Ström et al. (2012) [47] Sweden 17,647 ALE 84–88 56 days Started treatment in 2006: 67/–
Started treatment in 2009: 52/–
van Boven et al. (2013) [61] Netherlands 8,610 ALE–ETI–IBA–RIS–other 76 30 days 59/46
van den Boogaard et al.
(2006) [48]
Netherlands 14,760 ALE–ETI–RIS 100 7 days 44/27
Vanelli et al. (2009) [49] USA 168,640 Not specified 91–94 30 days Treatment-experienced: 45/–
Treatment-naïve: 20/–
Wade et al. (2012) [63] USA 33,558 ALE–IBA–RIS–other 94 90 days 45/–
Weiss et al. (2007) [56] USA 165,955 ALE–RIS/IBA 100 30 days ALE–RIS: 12/– IBA: 10/–
Weycker et al. (2006) [50] USA 12,538 ALE–RIS–other 100 90 days Weekly: 57/39
Daily: 50/33
Xu et al. (2013) [66] USA 41,461 ALE–IBA–RIS–other 92–95 90 days Commercial: 42/–
MAPD: 41/–
Yeaw et al. (2009) [51] USA 10,268 ALE–ETI–IBA–RIS–other 94 60 days 41/23
Yu et al. (2012) [52] Taiwan 3,589 ALE–other 91 30 days 51/36
Ziller et al. (2012) [62] Germany 195,191 ALE/ETI/IBA/RIS 86–92 183 days ALE 70 mg: 45/–
ETI: 43/–
IBA 150 mg: 51/
RIS 35 mg: 35/–
–, estimates are for all reported treatments; /, estimates are for separate treatments
ALE alendronate; DIN-LINK Doctors’ Independent Network Database; ETI etidronate; GPRD General Practice Research Database; IBA oral
ibandronate; MAPD Medicare Advantage Prescription Drug; MEDIPLUS IMS Disease Analyzer, not specified no reporting for specific oral
bisphosphonates, other other anti-osteoporosis treatments (e.g., strontium ranelate, raloxifene, zoledronate, and hormone replacement therapy), RIS,
risedronate
Osteoporos Int (2015) 26:2401–2411 2407
BPs which also used the same database [6, 47]. Additionally,
the majority of women in our study had previously received
other anti-osteoporosis therapies; this is not surprising given
that most women are prescribed oral BPs as their first line of
treatment and subsequently switch to another treatment if they
do not respond or experience intolerable side effects or dosing
inconvenience. We estimated 12- and 24-month persistence
with denosumab therapy to be 83 and 62 %, respectively,
using a permissible gap of 56 days (8 weeks). The length of
this gap is somewhat arbitrary and was chosen to be consistent
with that used in previous studies of persistence using the
same database [6, 47]. Varying the permissible gap to 30,
90, and 180 days resulted in estimated persistence rates of
78, 84, and 87 %, respectively, at 12 months, indicating that
the estimates were robust.
Women who had received previous anti-osteoporosis ther-
apies were more likely to persist with denosumab than treat-
ment-naïve women. One possible explanation for this finding
is that treatment-experienced women are more informed about
their disease and receive more information from their prescrib-
er. Filling a prescription for calcium and/or vitamin D supple-
mentation in the first 6 months after initiating denosumab was
significantly associated with persistence, with those who filled
prescriptions having a higher persistence rate than those who
did not. Similar results were reported by Cotte et al. [33],
who found that the rate of persistence was higher in women
taking calcium and vitamin D supplementation than in those
who did not take such supplements. While the reason for this
is not clear, a possible explanation is that calcium and vitamin
D supplementation is an indicator of high risk and, therefore,
high disease awareness. Finally, women receiving gluco-
corticoids before initiating denosumab had lower rates
of persistence than those who had no experience of
glucocorticoids. Similar results have been reported else-
where for other anti-osteoporosis treatments [6, 44, 53],
and further study is warranted to elucidate the reasons
for the association between persistence and glucocorticoid
use.
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Fig. 4 Estimates of 12-month
persistence with oral
bisphosphonate treatment black
square individual study, black
diamond pooled estimate. Data
are given as percentage (95 %
confidence interval. Citation
numbers of the studies detailed in
this figure are given in Table 3
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Persistence with oral bisphosphonates
The literature review identified 40 retrospective studies
reporting at least one estimate of 12- or 24-month persistence
with oral BPs, using varying methodologies. While all studies
were similar in terms of how persistence was defined, they
varied in the size of the permissible gap, which is directly
related to the probability of being defined as non-persistent.
Other study design heterogeneities concerned the possibility
of a patient accumulating prescriptions or switching between
dosages, dosing intervals, types of BP, and differences in
study population. Less obvious differences, which were not
systematically captured in our review, related to data quality
and completeness, under-reporting by family physicians, and
administrative hurdles. As well as methodological heteroge-
neity, the results are likely to have been influenced by other
factors, such as types of healthcare organization, approaches
to patient monitoring, drug reimbursement levels, and popu-
lation disease awareness.
The pooled estimate from our literature review showed that
45 % of patients were persistent with oral BP therapy after
12 months. This relatively low persistence can possibly be
explained by the asymptomatic nature of osteoporosis [68]
and the complicated administration of oral BPs, whereby the
tablet is taken under fasting conditions and with the patient
remaining in an upright position for about an hour to avoid
oesophageal reflux and oesophagitis, which, although infre-
quent, has been reported [69].
The two Swedish studies identified in the literature review
were based on the Swedish Prescribed Drug Register. They
estimated 12-month persistence with oral BPs to be 51 and
67 %, and 24-month persistence to be 25 % [6, 47]. It is worth
noting that the estimate of 67 % was derived before the intro-
duction of generic alendronate, which is likely to have caused
a drop in persistence. These estimates for persistence with oral
BP therapy are lower than the rates observed with denosumab
using the same database. The permissible gap was identical to
that in the present study (56 days); the only major difference
was that patients were allowed to accumulate medicine in the
studies of oral BPs.
Limitations
While retrospective register studies are based on historical
prescription data and, hence, avoid the reporting bias that
can arise in prospective studies, pharmaceuticals administered
in hospitals are not captured by the Swedish Prescribed Drug
Register and thus have not been included in our analysis. It is
estimated that less than 10 % of sold denosumab doses have
been administered in hospitals. By not including denosumab
administered in hospitals, we may have not identified women
who started treatment earlier than was recorded in the database
and so we may have underestimated the true persistence rate;
however, these women may be atypical and, to a large extent,
may have been given denosumab for reasons related to cancer
diagnoses. A register of prescriptions does not provide any
assurance that the dose was actually taken; therefore, persis-
tence with denosumab may have been overestimated in this
study. Another limitation of retrospective data is that all vari-
ables of interest may not be available, and it was not possible
in this database analysis to control for bone mineral density,
concomitant medicine use, comorbidities, lifestyle factors,
and socioeconomic variables, all of which may be important
predictors of persistence [57].
The literature review included all identified retrospective
studies on oral BPs that reported at least one estimate of either
12- or 24-month persistence, with no other quality require-
ment for inclusion. Some persistence estimates may conse-
quently have been derived from data of insufficient quality
for a robust analysis. In addition, there was heterogeneity be-
tween the studies. With this in mind, the pooled estimates and
the comparisons between the studies need to be interpreted
with some caution. Moreover, the analysis did not consider
persistence with other anti-osteoporosis drugs such as zoledro-
nic acid and intravenous bisphosphonates. Persistence with
these treatments, which are administered less frequently than
oral BPs, has previously been shown to be higher than with
oral BPs [62].
Conclusion
Persistence with denosumab in women with PMO in Sweden
was found to be approximately two-fold higher than pooled
persistence rates from a meta-analysis of retrospective data on
oral BPs. Our results from clinical practice are consistent with
previous reports of persistence with denosumab, in both a
clinical trial setting and studies of routine practice.
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